DPC was the week’s only clean handoff from filing work to public trading. Doncasters launched at $28 to $32, then priced an upsized 27,858,585-share IPO at $33 and raised about $919.3 million before expenses. The same pricing release said the company also expected roughly $144 million from previously disclosed concurrent private placements, with proceeds earmarked largely for debt reduction, including the shareholder PIK loan. A June 22 free-writing prospectus separately showed how much of that support was already being organized off the tape, including a proposed $75 million QIA private placement at the IPO price. Even so, Yahoo Finance data show DPC closed its June 25 debut at $46.88 and finished June 26 at $47.15, which is the kind of aftermarket confirmation the rest of the calendar did not get.
Doncasters describes itself as a specialist manufacturer of precision engine components for aerospace and industrial gas turbines, and its amended S-1 laid out the broader case: $837 million of 2025 revenue, a business tilted toward aerospace and industrial gas turbine demand, and a capital structure still being normalized after an 85% reduction in the shareholder PIK loan principal. IPOGrid reads that as the week’s clearest signal: large industrial paper can still clear if the story is conventional, the debt cleanup is explicit, and buyers can see a real public-market benchmark on day one.
Lime advanced, but the balance sheet is the story
Lime launched its roadshow for 6,956,522 shares at $24 to $26, with Uber-affiliated buyers indicating interest in up to $20 million of stock. The appeal is easy to see in the operating file. Neutron’s amended S-1 says revenue climbed from $522.0 million in 2023 to $686.6 million in 2024 and $886.7 million in 2025, while the Uber integration still generated about 14% of 2025 revenue.
But the reviewer’s concern is that this is at least as much a refinancing and market-access transaction as a straightforward growth IPO. The same S-1/A disclosed a material weakness in internal control and said the auditor included substantial-doubt going-concern language. As of March 31, 2026, Lime had about $261.3 million of cash, yet it also said roughly $845.8 million was due within twelve months of the issuance of its March-quarter financial statements. That does not kill the deal, but our interpretation is that buyers are being asked to underwrite a financing bridge first and a micromobility franchise second.
ITG and CopperTech are the real next tests
ITG launched a 19,512,196-share Nasdaq IPO at $19 to $22, and the company was unusually direct about what the cash is for: repaying outstanding principal under its revolving credit facility and term loan facility. The amended S-1 is big enough to matter, with about $1.2 billion of 2025 revenue, $6.2 million of net income, a workforce above 10,000, and $2.9 billion of total backlog. IPOGrid would frame ITG as a high-quality calendar test, but still a leveraged one.
CopperTech launched with similarly serious size: 23,529,412 shares at $16 to $18, built around Konkola Copper Mines in Zambia. But the S-1/A makes clear this is not a simple U.S. mining IPO. Vedanta will still control about 88.1% of the common stock after the offering, the issuer is a carve-out vehicle for Konkola Copper Mines, and the structure leaves public investors underwriting commodity upside alongside parent-company and governance complexity. That can work, but the structure appears to us materially more demanding than the headline deal size suggests.
Everything smaller still looks provisional
The smaller end of the file stayed crowded but not especially convincing. Carbon Zero Technologies amended a selling-shareholder ADS deal where the company says it will not receive proceeds from the shareholder ADSs. ChainOn filed into the week with a $4 to $6 range. Gold Stone Technical filed an F-1 for a microcap listing effort. Arterior Solutions amended a self-underwritten offering that is still only trying to raise $180,000. The point is not that these names cannot trade. It is that none of them changed the week’s center of gravity.
Decoy Therapeutics got an EFFECT on June 24, but by June 26 it was already back with $3.5 million of upfront PIPE proceeds and a structure that could reach $21 million if clinical milestones are met. IQM had already cleared SEC effectiveness earlier in June, and Real Asset Acquisition shareholders approved the business combination on June 25. Those are both valid forms of capital formation. They are also reminders that much of the week’s forward motion came from alternative routes rather than classic IPO price discovery.
That is why the week mattered. One issuer traded and traded well. One high-profile consumer name pressed ahead despite balance-sheet strain. Two larger roadshows moved into live marketing with leverage, control, or carve-out questions still attached. Everything else still looks like a waiting room. The calendar is open enough to reward a clean structure, but not broad enough to hide the hard questions.